BR0210532A - Derivados de naftil benzofurano como inibidores do inibidor-1 de ativador de plasminogênio (pai-1) - Google Patents
Derivados de naftil benzofurano como inibidores do inibidor-1 de ativador de plasminogênio (pai-1)Info
- Publication number
- BR0210532A BR0210532A BR0210532-2A BR0210532A BR0210532A BR 0210532 A BR0210532 A BR 0210532A BR 0210532 A BR0210532 A BR 0210532A BR 0210532 A BR0210532 A BR 0210532A
- Authority
- BR
- Brazil
- Prior art keywords
- aryl
- heteroaryl
- alkyl
- substituted
- cycloalkyl
- Prior art date
Links
- -1 Naphthyl benzofuran derivatives Chemical class 0.000 title abstract 5
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 title abstract 4
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 8
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000003107 substituted aryl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000005024 alkenyl aryl group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical class C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 abstract 1
- 206010051055 Deep vein thrombosis Diseases 0.000 abstract 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 abstract 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 abstract 1
- 206010047249 Venous thrombosis Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002877 alkyl aryl group Chemical group 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000003527 fibrinolytic agent Substances 0.000 abstract 1
- 230000003480 fibrinolytic effect Effects 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 208000005069 pulmonary fibrosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29970201P | 2001-06-20 | 2001-06-20 | |
| PCT/US2002/019231 WO2003000671A1 (en) | 2001-06-20 | 2002-06-18 | Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0210532A true BR0210532A (pt) | 2004-06-22 |
Family
ID=23155895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0210532-2A BR0210532A (pt) | 2001-06-20 | 2002-06-18 | Derivados de naftil benzofurano como inibidores do inibidor-1 de ativador de plasminogênio (pai-1) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6599925B2 (enExample) |
| EP (1) | EP1401822A1 (enExample) |
| JP (1) | JP4476624B2 (enExample) |
| CN (1) | CN1308320C (enExample) |
| AR (1) | AR036100A1 (enExample) |
| BR (1) | BR0210532A (enExample) |
| CA (1) | CA2449844A1 (enExample) |
| MX (1) | MXPA03011400A (enExample) |
| TW (1) | TWI240723B (enExample) |
| WO (1) | WO2003000671A1 (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7374886B2 (en) | 1999-04-09 | 2008-05-20 | Rigshospitalet | Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer |
| TWI224101B (en) * | 2001-06-20 | 2004-11-21 | Wyeth Corp | Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| US7291639B2 (en) * | 2001-06-20 | 2007-11-06 | Wyeth | Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| WO2003000253A1 (en) | 2001-06-20 | 2003-01-03 | Wyeth | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| ATE411288T1 (de) * | 2002-12-10 | 2008-10-15 | Wyeth Corp | Aryl-, aryloxy- und alkyloxysubstituierte 1h- indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1) |
| US7348351B2 (en) * | 2002-12-10 | 2008-03-25 | Wyeth | Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| UA80453C2 (en) * | 2002-12-10 | 2007-09-25 | Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
| US7078429B2 (en) * | 2002-12-10 | 2006-07-18 | Wyeth | Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| US7442805B2 (en) * | 2003-09-25 | 2008-10-28 | Wyeth | Substituted sulfonamide-indoles |
| US7163954B2 (en) * | 2003-09-25 | 2007-01-16 | Wyeth | Substituted naphthyl benzothiophene acids |
| US7351726B2 (en) * | 2003-09-25 | 2008-04-01 | Wyeth | Substituted oxadiazolidinediones |
| US7141592B2 (en) * | 2003-09-25 | 2006-11-28 | Wyeth | Substituted oxadiazolidinediones |
| US7446201B2 (en) | 2003-09-25 | 2008-11-04 | Wyeth | Substituted heteroaryl benzofuran acids |
| US7420083B2 (en) * | 2003-09-25 | 2008-09-02 | Wyeth | Substituted aryloximes |
| US7268159B2 (en) * | 2003-09-25 | 2007-09-11 | Wyeth | Substituted indoles |
| US7582773B2 (en) * | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
| US7265148B2 (en) * | 2003-09-25 | 2007-09-04 | Wyeth | Substituted pyrrole-indoles |
| US7411083B2 (en) * | 2003-09-25 | 2008-08-12 | Wyeth | Substituted acetic acid derivatives |
| US7534894B2 (en) * | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
| US7332521B2 (en) * | 2003-09-25 | 2008-02-19 | Wyeth | Substituted indoles |
| US7342039B2 (en) * | 2003-09-25 | 2008-03-11 | Wyeth | Substituted indole oximes |
| WO2005094863A1 (en) * | 2004-03-30 | 2005-10-13 | Den Kgl.Veterinær-Og Landbohøjskole | Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and decting protease inhibitors |
| CN101044127A (zh) | 2004-08-23 | 2007-09-26 | 惠氏公司 | 用作纤溶酶原激活剂抑制剂－1的噻唑基－萘基酸 |
| KR20070055563A (ko) | 2004-08-23 | 2007-05-30 | 와이어쓰 | 혈전증 및 심혈관 질병의 치료에 유용한 플라스미노겐활성화제 억제제 타입-1(ｐａｉ-1)의 조절제로서의옥사졸로-나프틸 산 |
| MX2007002177A (es) * | 2004-08-23 | 2007-04-02 | Wyeth Corp | Acidos de pirrolo-naftilo como inhibidores de pai-1. |
| BRPI0614340A2 (pt) * | 2005-08-17 | 2011-04-12 | Wyeth Corp | indóis substituìdos e métodos de seu uso |
| AU2007217363A1 (en) * | 2006-02-27 | 2007-08-30 | Wyeth | Inhibitors of PAI-1 for treatment of muscular conditions |
| US7884234B2 (en) * | 2006-10-12 | 2011-02-08 | Institute Of Medicinal Molecular Design, Inc. | N-phenyloxamide derivatives |
| EP2080751A4 (en) | 2006-10-12 | 2011-06-22 | Inst Med Molecular Design Inc | CARBON ACID DERIVATIVE |
| EP2201946A4 (en) | 2007-10-23 | 2012-01-25 | Inst Med Molecular Design Inc | HAMMER OF PAI-1 PRODUCTION |
| JPWO2009125606A1 (ja) | 2008-04-11 | 2011-08-04 | 株式会社医薬分子設計研究所 | Ｐａｉ−１阻害剤 |
| US8633245B2 (en) * | 2008-04-11 | 2014-01-21 | Institute Of Medicinal Molecular Design, Inc. | PAI-1 inhibitor |
| CA2744555A1 (en) | 2008-11-26 | 2010-06-03 | Five Prime Therapeutics, Inc. | Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2 |
| WO2010129049A1 (en) * | 2009-05-05 | 2010-11-11 | Sloan-Kettering Institute For Cancer Research | Benzofuran-4,5-diones as selective peptide deformylase inhibitors |
| CN102850451B (zh) * | 2011-06-29 | 2014-05-07 | 辽宁诺康生物制药有限责任公司 | 具有抑制纤溶酶活性的重组textilinin-1及其制备方法和应用 |
| DK3395354T3 (da) | 2015-12-18 | 2024-06-03 | Talengen Int Ltd | Plasminogen til anvendelse i behandling af diabetisk nefropati |
| CN106890324A (zh) * | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗糖尿病肾病的方法 |
| CA3047176C (en) | 2016-12-15 | 2021-11-30 | Talengen International Limited | Use of plasminogen for promoting secretion of insulin in treatment of diabetes |
| CN114957176A (zh) * | 2022-07-01 | 2022-08-30 | 河南中医药大学第一附属医院 | 人血管紧张素转化酶抑制剂化合物和合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1464242A (en) * | 1974-04-18 | 1977-02-09 | Smithkline Corp | Benzoyl benzofurans and compositions comprising them |
| US4024273A (en) | 1974-06-20 | 1977-05-17 | Smithkline Corporation | Coronary vasodilator and anti-anginal compositions comprising substituted benzofurans and benzothiophenes and methods of producing coronary vasodilation and anti-anginal activity |
| ZA825413B (en) | 1981-08-26 | 1983-06-29 | Pfizer | Thromboxane synthetase inhibitors, processes for their production, and pharmaceutical compositions comprising them |
| ZA928276B (en) * | 1991-10-31 | 1993-05-06 | Daiichi Seiyaku Co | Aromatic amidine derivates and salts thereof. |
| US6756388B1 (en) | 1993-10-12 | 2004-06-29 | Pfizer Inc. | Benzothiophenes and related compounds as estrogen agonists |
| CA2134192A1 (en) | 1993-11-12 | 1995-05-13 | Michael L. Denney | 5, 6-bicyclic glycoprotein iib/iiia antagonists |
| CA2207141A1 (en) * | 1996-07-15 | 1998-01-15 | David Thompson Berg | Benzothiophene compounds, and uses and formulations thereof |
| US6110963A (en) | 1998-05-12 | 2000-08-29 | American Home Products Corporation | Aryl-oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia |
-
2002
- 2002-06-10 TW TW091112529A patent/TWI240723B/zh not_active IP Right Cessation
- 2002-06-18 US US10/174,166 patent/US6599925B2/en not_active Expired - Fee Related
- 2002-06-18 JP JP2003507076A patent/JP4476624B2/ja not_active Expired - Lifetime
- 2002-06-18 WO PCT/US2002/019231 patent/WO2003000671A1/en not_active Ceased
- 2002-06-18 BR BR0210532-2A patent/BR0210532A/pt not_active IP Right Cessation
- 2002-06-18 CN CNB028161874A patent/CN1308320C/zh not_active Expired - Fee Related
- 2002-06-18 EP EP02747904A patent/EP1401822A1/en not_active Withdrawn
- 2002-06-18 MX MXPA03011400A patent/MXPA03011400A/es active IP Right Grant
- 2002-06-18 CA CA002449844A patent/CA2449844A1/en not_active Abandoned
- 2002-06-20 AR ARP020102314A patent/AR036100A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1543456A (zh) | 2004-11-03 |
| AR036100A1 (es) | 2004-08-11 |
| TWI240723B (en) | 2005-10-01 |
| US6599925B2 (en) | 2003-07-29 |
| WO2003000671A1 (en) | 2003-01-03 |
| JP4476624B2 (ja) | 2010-06-09 |
| CA2449844A1 (en) | 2003-01-03 |
| MXPA03011400A (es) | 2004-04-05 |
| CN1308320C (zh) | 2007-04-04 |
| JP2004534824A (ja) | 2004-11-18 |
| US20030018067A1 (en) | 2003-01-23 |
| EP1401822A1 (en) | 2004-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0210532A (pt) | Derivados de naftil benzofurano como inibidores do inibidor-1 de ativador de plasminogênio (pai-1) | |
| BR0316586A (pt) | Derivados de diidropirano indol-3, 4-dione e derivados de 3-ácido oxoacético 2-hidroximetilindol substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1) | |
| WO2001081312A3 (en) | Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore | |
| ATE411288T1 (de) | Aryl-, aryloxy- und alkyloxysubstituierte 1h- indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1) | |
| NO950297D0 (no) | Prolinamidderivater | |
| YU71102A (sh) | Supstituisani amidi benzoeve kiseline i njihova primena kao sredstva za lečenje | |
| EA200101085A1 (ru) | Гидроксамовые кислоты, производные ароматических сульфонов, - ингибиторы металлопротеаз | |
| DK1104760T3 (da) | Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler | |
| CY1106901T1 (el) | Παραγωγα υποκατεστημενου ινδολο οξεος σαν αναστολεις του αναστολεα-1 ενεργοποιητη πλασμινογονου (pai-1) | |
| IL154537A0 (en) | 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith | |
| DK1104759T3 (da) | Heteroarylphenylpyrazolforbindelser som antiinflammatoriske/analgetiske midler | |
| PT787726E (pt) | Novo composto, processo para a sua producao e agente tumoral | |
| LV12291A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
| EA200101077A1 (ru) | Композиция для профилактики или лечения слабоумия, включающая производное гидроксикоричной кислоты или экстракт растения рода angelicae, содержащий его | |
| EE200000298A (et) | Bifenüülamidiini derivaadid, eelravim, vere koagulatsiooniinhibiitor ning profülaktiline ja terapeutiline toimeaine tromboosi või emboolia vastu | |
| ES2100222T3 (es) | Derivados del acido aminoalcansulfonico y compuestos farmaceuticos a utilizar para prevenir o tratar afecciones cardiacas. | |
| EA200401519A1 (ru) | N- ациламинобензольные производные в качестве селективных ингибиторов моноаминооксидазы b | |
| DK1018511T3 (da) | Isochromanforbindelser og fremgangsmåde til deres fremstilling | |
| BR0014615A (pt) | Derivado de ácido fosfÈnico que apresenta atividade inibidora contra carboxipeptidase b | |
| WO2002064552A8 (en) | 1g(a)-AMINO-N-HYDROXY-ACETAMIDE DERIVATIVES | |
| EA200400523A1 (ru) | Производные [[2-(амино-3,4-диоксо-1-циклобутен-1-ил)амино]алкил] кислоты, применяемые для лечения боли | |
| BR0214293A (pt) | Composto e métodos para tratar um paciente que tenha, ou de prevenir um paciente de adquirir, uma doença ou condição e para produzir um composto ou um sal ou éster farmaceuticamente aceitável do mesmo | |
| EP1333024A4 (en) | PEPTIDE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, METHODS OF PREPARATION AND USE THEREOF | |
| IL156203A0 (en) | Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders | |
| EP1099440A4 (en) | THERAPEUTIC AGENTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: ALTERADA DA INT.CL: C07D 307/79, C07D 405/12, A61K 31/34 Ipc: C07D 307/79 (2011.01), C07D 405/12 (2011.01), A61K |
|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011. |